This report was first published by Endpoints News. To see the original version, click here
Roche’s breast cancer pill, which the company recently said had the potential to become its biggest-ever selling drug, has failed in what is arguably its most important Phase 3 trial.
The persevERA study was assessing giredestrant as a frontline therapy for certain breast cancer patients, and success would have been necessary for the asset to achieve Roche’s lofty sales goals. But the drug did not demonstrate a statistically significant improvement in progression-free survival over a placebo-containing regimen, Roche said Monday.
您已阅读15%（624字），剩余85%（3530字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。